Affinage

SRSF6

Serine/arginine-rich splicing factor 6 · UniProt Q13247

Length
344 aa
Mass
39.6 kDa
Annotated
2026-06-10
76 papers in source corpus 47 papers cited in narrative 47 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SRSF6 (SRp55/B52) is an essential SR-family splicing factor that uses two RRM domains to recognize purine-rich exonic and intronic elements and thereby governs constitutive and concentration-dependent alternative splicing of hundreds of pre-mRNAs across development, apoptosis, and tissue differentiation (PMID:7935465, PMID:8035814, PMID:9111335, PMID:33376132). Its sequence specificity is built on a GAA-triplet/purine-rich consensus bound predominantly in coding regions, with binding-site position dictating splicing outcome; the first RRM and RRM2 are each functionally critical, and cooperative or heterodimeric binding tunes enhancer/silencer activity (PMID:7565780, PMID:9111335, PMID:9436904, PMID:29114070, PMID:33376132). Through this activity SRSF6 controls a broad target set — including troponin T, calcitonin/CGRP, FGFR1, ZO-1, tau exon 10, Fas, MUSK exon 10, and the pro-apoptotic regulators BIM and BAX — and the developmental consequences of its dosage are stringent, as overexpression or loss is deleterious and Srsf6 nullizygosity is embryonic lethal in mice (PMID:9436904, PMID:12549914, PMID:15604250, PMID:22767602, PMID:23648111, PMID:29114070, PMID:32820193, PMID:36409059, PMID:35454897, PMID:40161265). SRSF6 function is set by an extensive regulatory layer: SRPK1 and Clk/Sty phosphorylate the RS domain to control nuclear-speckle localization and proteasomal stability, DRAK2 binding blocks SRPK1-mediated phosphorylation, and Dyrk1A phosphorylates the proline-rich domain to suppress activity, while its abundance is further governed at the RNA level by autoregulatory poison-exon inclusion in hypoxia and by lncRNA/RNA-modification inputs (PMID:12549978, PMID:22767602, PMID:23648111, PMID:34614409, PMID:36620874, PMID:40083919). Beyond splicing, SRSF6 associates with and delivers Topoisomerase I to actively transcribed loci to couple transcription with mRNA release, organizes nuclear-speckle cohesion, and in innate immune cells controls the BAX isoform balance that sets the threshold for mitochondrial DNA liberation and cGAS-STING signaling (PMID:20862310, PMID:36409059, PMID:36620874). It behaves as a proto-oncogene that is amplified and overexpressed in lung, colon, skin and other cancers, where it remodels splicing of tumor suppressors and oncogenic isoforms (e.g. tenascin C, ZO-1) to drive proliferation, EMT, and metastasis (PMID:23132731, PMID:24440982, PMID:27443606, PMID:29114070).

Mechanistic history

Synthesis pass · year-by-year structured walk · 27 steps
  1. 1994 High

    Established that SRSF6 is an essential gene whose product acts as a splicing factor but is not universally required for all pre-mRNA splicing, introducing the concept of target/tissue specificity.

    Evidence Drosophila B52 null deletion with genomic rescue and endogenous pre-mRNA RT-PCR; in vitro splicing and transgenic overexpression

    PMID:7935465 PMID:8035814

    Open questions at the time
    • Identity of specific endogenous targets requiring B52 not yet defined
    • Molecular basis of concentration-dependence unresolved
  2. 1994 Medium

    Linked SRSF6 distribution to active transcription, raising the possibility of co-transcriptional function.

    Evidence Immunofluorescence on polytene chromosomes and UV cross-linking showing transcription-dependent localization bracketing RNA Pol II

    PMID:8186467

    Open questions at the time
    • Whether co-localization reflects a direct mechanistic coupling to transcription not established here
    • Single-lab observation
  3. 1995 High

    Pinpointed the RRM1 RNA-binding domain as critical for splicing function in vivo via a dominant point mutant that alters splice-site choice.

    Evidence Genetic screen isolating the B52ED β4-strand allele with in vivo splicing assays at doublesex and white

    PMID:7565780

    Open questions at the time
    • Structural mechanism by which the β4 residue alters binding not resolved
    • Relationship to RRM2 contribution untested
  4. 1997 High

    Defined the biochemical basis of RNA recognition — both RRMs engage RNA and the RS domain is dispensable for binding.

    Evidence SELEX from random RNA pools with mutagenesis and enzymatic structure probing

    PMID:9111335

    Open questions at the time
    • Relationship between the in vitro hairpin and physiological enhancer motifs unclear
    • Role of RS domain after binding not addressed
  5. 1998 High

    Demonstrated quantitative, cooperative, sequence-specific binding to a natural exonic splicing enhancer and tied binding affinity to splicing outcome.

    Evidence EMSA with purified SRp55, Hill analysis, chemical interference, and mutagenesis correlated with in vivo cardiac troponin T splicing

    PMID:9436904

    Open questions at the time
    • Generality of cooperative binding across other enhancers unknown
    • In vivo stoichiometry not measured
  6. 1999 Medium

    Showed SRSF6 has target-selective effects distinct from other SR proteins and that its abundance is dynamically regulated during cell activation.

    Evidence Overexpression and antisense inhibition in cells with CD45 isoform readout during T-cell activation

    PMID:10092085

    Open questions at the time
    • Direct binding to CD45 pre-mRNA not demonstrated
    • Single-lab, indirect mechanism
  7. 2003 High

    Consolidated the ESE-binding model across multiple substrates and established RS-domain phosphorylation by Clk/Sty as a switch controlling speckle localization and proteasomal turnover.

    Evidence Calcitonin ESE mutagenesis with in vitro/in vivo splicing; UV cross-linking with hTra2β; DRB/Clk-Sty phosphorylation mapping, localization, proteasome inhibition and deletion mutagenesis

    PMID:12531473 PMID:12549914 PMID:12549978

    Open questions at the time
    • Kinase(s) responsible for physiological RS phosphorylation in cells not fully resolved
    • Link between phosphorylation state and target selection unmapped
  8. 2004 High

    Established SRSF6 as a major, non-redundant regulator of a clinically relevant alternative exon (FGFR1 α-exon).

    Evidence UV cross-linking/IP plus RNAi knockdown with quantitative α-exon RT-PCR

    PMID:15604250

    Open questions at the time
    • Functional consequence of FGFR1 isoform switch in disease not tested here
  9. 2005 Medium

    Revealed that SRSF6 can act as a splicing silencer in a heterodimer with SRp30c, broadening its regulatory repertoire beyond enhancement.

    Evidence Deletion analysis, protein-protein/protein-RNA assays, minigene splicing and co-IP of the SRp30c–SRp55 complex on tau exons 2 and 10

    PMID:15695522

    Open questions at the time
    • Structural basis of heterodimer-mediated steric block not resolved
    • Single-lab heterodimer model
  10. 2006 High

    Placed SRSF6 in a cell-cycle control pathway by showing it is required for proper splicing of a key transcriptional repressor.

    Evidence Drosophila genetic epistasis, clonal S-phase assays and intronless de2f2 rescue confirming a splicing-dependent role upstream of dE2F2

    PMID:16611989

    Open questions at the time
    • Conservation of this cell-cycle role in mammals untested
  11. 2007 High

    Demonstrated tissue- and target-specific developmental roles, where SRSF6 dosage shapes alternative isoforms with distinct biological activity.

    Evidence In vivo isoform-specific overexpression of eyeless variants with DNA-binding assays; microarray splicing analysis and neuronal phenotyping in the developing eye

    PMID:17283056 PMID:17327915

    Open questions at the time
    • Direct binding sites within eyeless not mapped
    • Mammalian counterparts of these targets unknown
  12. 2008 Medium

    Connected SRSF6 splicing activity to apoptosis regulation and coagulation through its control of pro-/anti-apoptotic and tissue factor isoforms.

    Evidence siRNA knockdown with splice-specific microarray (KSR1/ZAK/mda7, Fas); ESE mutagenesis and UV cross-linking on tissue factor exon 5

    PMID:18315555 PMID:18571879

    Open questions at the time
    • Direct binding to all apoptosis targets not validated
    • Single-lab studies
  13. 2010 High

    Uncovered a non-splicing role: SRSF6 physically partners with Topoisomerase I to deliver it to transcribed chromatin and couple transcription to mRNA release; also defined roles in HIV-1 RNA metabolism.

    Evidence Reciprocal co-IP, in vitro phosphorylation, RNAi mislocalization and mRNA FISH for Topo I; HIV-1 splicing reporters and domain mutants for Gag translation and vpr/env mRNA control

    PMID:20427542 PMID:20685659 PMID:20862310

    Open questions at the time
    • Whether Topo I delivery generalizes beyond heat-shock loci untested
    • Mechanism coupling RS phosphorylation to Topo I handoff unresolved
  14. 2012 High

    Identified Dyrk1A as a kinase regulating SRSF6 through proline-rich-domain phosphorylation, adding a second phospho-regulatory input that tunes tau exon 10 inclusion.

    Evidence Co-IP, in vitro kinase assay, tau minigene splicing, siRNA knockdown and RS-domain deletion with speckle imaging

    PMID:22767602

    Open questions at the time
    • Interplay between Dyrk1A and SRPK1/Clk phosphorylation not integrated
    • In vivo relevance to tauopathy untested
  15. 2013 High

    Established SRSF6 as an amplified proto-oncogene that drives proliferation, chemoresistance and tumorigenicity by generating oncogenic splice isoforms.

    Evidence Copy-number analysis, stable overexpression, xenograft tumorigenicity and shRNA knockdown with splice-isoform RT-PCR; UV cross-linking/minigene mutagenesis defining direct BIM intronic binding

    PMID:23132731 PMID:23648111

    Open questions at the time
    • Comprehensive oncogenic target set not yet enumerated
    • Driver versus passenger status of individual isoforms unclear
  16. 2014 High

    Provided in vivo proof that SRSF6 overexpression is oncogenic in skin, defining genome-wide targets and a stem-cell-depletion mechanism.

    Evidence Transgenic mouse overexpression with RNA-seq, tenascin C exon binding, histology, LGR6+ stem cell quantification and isoform-rescue wound-healing assays

    PMID:24440982

    Open questions at the time
    • Mechanism linking splicing changes to stem-cell depletion incompletely defined
  17. 2015 Medium

    Showed SRSF6 promotes cell growth via myc upregulation, identifying genetic modifiers of its growth effect.

    Evidence Drosophila bristle-lineage overexpression with a genetic modifier screen and myc RT-PCR (brat, lilli)

    PMID:25680814

    Open questions at the time
    • Whether myc upregulation is splicing-dependent not established
    • Single-organism observation
  18. 2016 Medium

    Identified lncRNAs as regulators of SRSF6 activity and extended its oncogenic role to EMT and metastasis; also placed it downstream in an RBM4a–Nova1 splicing cascade controlling brown adipocyte development.

    Evidence Co-IP of LINC01133–SRSF6 with migration/invasion and in vivo metastasis; RBM4a knockout with Nova1/SRSF6 isoform analysis and adipogenesis rescue

    PMID:27443606 PMID:27535496

    Open questions at the time
    • Direct splicing targets driving EMT not fully defined
    • Single-lab studies
  19. 2017 High

    Defined SRSF6 RRM2 as functionally key, mapped a direct ZO-1 binding site, and connected SRSF6 to controllable inhibition, identifying a small-molecule inhibitor.

    Evidence RIP-seq, gel shift, ZO-1 minigene, RRM2 deletion, virtual screening (indacaterol) and in vivo tumor assays; SRp55 RNA-seq in β-cells linking targets to apoptosis, mitochondria and insulin secretion

    PMID:29114070 PMID:29246973

    Open questions at the time
    • Selectivity of RRM2-targeting inhibitor not fully characterized
    • Direct β-cell targets only partly validated at the binding level
  20. 2018 Medium

    Extended the target repertoire to smooth-muscle myosin (MYH11) and circadian-clock intron splicing, reinforcing broad tissue-specific roles.

    Evidence siRNA knockdown with SMB-isoform RT-PCR in airway smooth muscle; Drosophila clock-neuron knockdown with dmpi8 splicing and sleep behavior

    PMID:29382842 PMID:30350466

    Open questions at the time
    • Direct binding to MYH11/per not all validated
    • Single-lab studies
  21. 2020 High

    Established the transcriptome-wide binding logic of SRSF6 — a purine-rich GAA-triplet motif bound in coding sequence with position-dependent outcomes — and confirmed broad DNA-repair-pathway splicing effects.

    Evidence iCLIP at nucleotide resolution with matched RNA-seq and ASO validation in β-cells; SRSF6 overexpression RNA-seq in HeLa; Srsf6 KO mice testing HTT splicing and revealing embryonic lethality

    PMID:32820193 PMID:32901876 PMID:33376132

    Open questions at the time
    • Rules linking motif position to enhancement versus silencing only partially formalized
    • Essential function underlying embryonic lethality not mechanistically pinned
  22. 2021 High

    Defined two convergent layers of SRSF6 abundance/activity control — lncRNA-mediated protein destabilization and a kinase-binding protein (DRAK2) that blocks SRPK1 phosphorylation — with disease consequences in gastric cancer and NASH.

    Evidence CRNDE RNA pulldown/co-IP/stability assay with PICALM minigene and PDX; DRAK2–SRSF6 co-IP, phosphoproteome/transcriptome and hepatic DRAK2 conditional knockout

    PMID:33397371 PMID:34614409

    Open questions at the time
    • How phospho-state changes redirect specific targets not mechanistically resolved
    • Relative contribution of stability versus phosphorylation control unclear
  23. 2022 High

    Revealed an innate-immune role: SRSF6 sets the BAX isoform balance that controls mitochondrial DNA release and cGAS-STING activation, and defined direct sequence requirements for Fas exon control.

    Evidence Macrophage loss-of-function with BAX-isoform RT-PCR, cGAS sensing, mtDNA quantification and apoptosis assays; Fas minigene mutagenesis with biotin-RNA pulldown defining the UGCCAA element

    PMID:35454897 PMID:36409059

    Open questions at the time
    • Upstream signals tuning SRSF6 upon pathogen sensing not fully mapped
    • Direct BAX binding site not defined in this work
  24. 2023 High

    Demonstrated autoregulation of SRSF6 levels by SRSF4-promoted poison-exon inclusion in hypoxia and tied SRSF6 dosage to nuclear-speckle integrity and the genomic stress response.

    Evidence CRISPR/Cas9 deletion of the poison-exon 3' splice site, overexpression in hypoxia, nuclear-speckle imaging, RNA-seq, proliferation and genomic-instability assays

    PMID:36620874

    Open questions at the time
    • How SRSF6 mechanistically maintains speckle cohesion not resolved
    • Trigger linking hypoxia to SRSF4 activation unclear
  25. 2024 Medium

    Connected SRSF6 to chromatin regulation by controlling HIRA splicing and H3.3 activity, modulating AR/E2F oncogenic pathways in prostate cancer.

    Evidence SRSF6 modulation with HIRA isoform RT-PCR, H3.3 activity, AR/E2F readouts and xenograft tumor growth

    PMID:39356765

    Open questions at the time
    • Direct SRSF6 binding to HIRA not shown
    • Single-lab study
  26. 2025 Medium

    Added RNA-modification and isoform-level inputs to SRSF6 regulation (NSUN2 m5C writing, AGGF1-driven exon-3 skipping) and extended its functional outputs to drug resistance and vascular development.

    Evidence MeRIP-seq with NSUN2 KO and UAP1 splicing in thyroid cancer; AGGF1 knockdown with SRSF6 isoform rescue in endothelial cells and zebrafish vascular assays; MUSK exon 10 minigene mutagenesis with SRSF1/SRSF6 cooperation

    PMID:40035560 PMID:40083919 PMID:40161265

    Open questions at the time
    • Functional differences between SRSF6 exon-3-skipped isoforms not detailed
    • Direct binding to UAP1/MUSK only partly mapped
  27. 2026 Medium

    Defined deubiquitination-based control of SRSF6 stability and provided the first structural characterization of its two RRMs.

    Evidence CircNSD2-scaffolded SRSF6–USP10 co-IP with K16 ubiquitination assay and TPM1 splicing in TNBC; solution NMR backbone/sidechain assignments and 15N-relaxation of RRM1 and ΨRRM2

    PMID:41808072 PMID:42102650

    Open questions at the time
    • NMR study lacks functional validation of structural features
    • Structure of the RNA-bound complex not determined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the multiple phospho-regulatory (SRPK1, Clk/Sty, Dyrk1A, DRAK2) and abundance-control (poison exon, m5C, lncRNA, deubiquitination) inputs are integrated to select among hundreds of position-dependent targets, and the structural basis of RNA recognition by the two-RRM module, remain unresolved.
  • No unified model linking SRSF6 phospho-state/abundance to specific target choice
  • No RNA-bound structure of the tandem RRMs
  • Mechanism of speckle cohesion and Topo I delivery not reconstituted

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 8 GO:0140110 transcription regulator activity 4 GO:0060090 molecular adaptor activity 2 GO:0045182 translation regulator activity 1
Localization
GO:0005634 nucleus 3 GO:0000228 nuclear chromosome 2 GO:0005654 nucleoplasm 2
Pathway
R-HSA-8953854 Metabolism of RNA 8 R-HSA-1643685 Disease 4 R-HSA-5357801 Programmed Cell Death 4 R-HSA-168256 Immune System 2 R-HSA-74160 Gene expression (Transcription) 2 R-HSA-1640170 Cell Cycle 1
Partners
CLK1DRAK2DYRK1ASRPK1SRSF1SRSF10TOP1USP10
Complex memberships
SRp30c–SRSF6 splicing-silencer heterodimernuclear speckle

Evidence

Reading pass · 47 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1994 B52/SRSF6 (Drosophila ortholog) is an essential gene required for larval development; null mutants are lethal at first and second instar stages, but B52 is not required for splicing of all pre-mRNAs in vivo, indicating tissue/target specificity. P-element remobilization to generate null deletion; genetic rescue by germ-line transformation with B52 genomic DNA; RT-PCR of endogenous pre-mRNAs in null larvae Molecular and cellular biology High 7935465
1994 B52/SRSF6 functions as both a general splicing factor and a regulator of 5' alternative splice site choice in a concentration-dependent manner in vitro; overexpression in transgenic flies adversely affects development in many cell types, indicating that its concentration is critical in vivo. In vitro splicing assays; transgenic fly overexpression; Western blot and whole-mount immunofluorescence Molecular and cellular biology High 8035814
1994 B52/SRSF6 colocalizes with RNA polymerase II on polytene chromosomes; its distribution at highly active heat-shock puffs brackets RNA polymerase II, and this distribution depends on transcription levels as shown by UV cross-linking. Immunofluorescence on polytene chromosomes; UV cross-linking in nonpolytene cells Molecular biology of the cell Medium 8186467
1995 A single amino acid change in the β4 strand of the first RRM of B52/SRSF6 (allele B52ED) acts as a dominant enhancer of RNA-processing defects and alters alternative splice site choice (favoring male-specific doublesex splice), establishing that the RRM1 RNA-binding domain is critical for B52 splicing function in vivo. Genetic screen; isolation of dominant and loss-of-function alleles; sequence comparison; in vivo splicing assays at doublesex and white loci Molecular and cellular biology High 7565780
1997 B52/SRSF6 binds a specific RNA hairpin loop structure (~20 nt) via both its RRM domains; the RS domain is not required for RNA binding. This was established by SELEX from random RNA pools followed by mutagenesis and enzymatic structure probing. SELEX (selection and amplification from random RNA pool); deletion/substitution mutagenesis of RNA; structure-specific enzymatic probing Molecular and cellular biology High 9111335
1998 SRp55/SRSF6 specifically binds a 30-nt exonic splicing enhancer (ESE) in avian cardiac troponin T exon 5 with apparent Kd ~60 nM; cooperative binding of at least two SRp55 proteins is required; mutations that alter exon inclusion in vivo correspondingly change SRp55 binding affinity; both purine-rich motifs in the ESE are required. Gel mobility retardation (EMSA) with purified SRp55; Hill plot analysis; chemical modification interference (kethoxal, DMS); mutagenesis correlated with in vivo splicing RNA (New York, N.Y.) High 9436904
1999 SRp55/SRSF6 does not induce skipping of CD45 exon 4 (unlike SF2/SC35/SRp40/SRp75); antisense inhibition of SRp55 induces exon 4 skipping, and SRp55 expression increases markedly upon T cell activation alongside CD45RA-to-CD45RO isoform switching. Overexpression in COS cells; antisense inhibition; flow cytometry for CD45 isoforms; Western blot European journal of immunology Medium 10092085
2000 B52/SRSF6 is the predominant SR protein in specific Drosophila tissues (e.g., brain); tissues where B52 is the major SR protein fail to splice the ftz pre-mRNA when B52 is deleted, while other tissues can use alternative SR proteins to substitute, explaining tissue-specific lethality. Immunodepletion of B52 from Kc cell nuclear extracts; homologous in vitro splicing assay; immunofluorescence of larval tissues; RT-PCR of ftz mRNA in B52-deletion tissue Molecular and cellular biology High 10594020
2003 SRp55/SRSF6 binds an exonic splice enhancer (ESE) in calcitonin exon 4; base changes that decrease SRp55 binding decrease calcitonin splicing in vitro and in vivo; base changes that increase affinity enhance calcitonin mRNA production; SRp55 levels correlate with calcitonin splicing across cell types; SRp55 overexpression stimulates calcitonin mRNA production. In vitro splicing assays; binding site mutagenesis; SRp55 overexpression in 293 cells; RT-PCR quantification of calcitonin mRNA Biochemistry High 12549914
2003 Human transformer 2β (hTra2β) and SRp55/SRSF6 specifically interact with the calcitonin exon 4 ESE; hTra2β is required for calcitonin splicing in vitro; SRp55 binding to the ESE contributes to calcitonin/CGRP alternative splicing regulation. UV cross-linking with HeLa nuclear extract; immunoprecipitation identification of 55-kDa band as SRp55; in vitro splicing assay with hTra2β Biochimica et biophysica acta Medium 12531473
2003 Hyperphosphorylation of SRp55/SRSF6 occurs specifically at the RS domain (induced by DRB or overexpression of Clk/Sty) and requires RNA-binding activity; hyperphosphorylated SRp55 relocalizes to enlarged nuclear speckles; Clk/Sty overexpression targets SRp55 for proteasomal degradation via a destabilization signal in the C-terminal 43-aa segment, with the adjacent RS domain critical for Clk/Sty-mediated degradation. DRB treatment; Clk/Sty overexpression; phosphorylation mapping; subcellular localization by immunofluorescence; proteasome inhibitor experiments; deletion mutagenesis The Biochemical journal High 12549978
2004 SRp55/SRSF6 binds an ESE in the FGFR1 α-exon (identified by UV cross-linking and immunoprecipitation); RNAi-mediated knockdown of SRp55 causes a 6–14-fold decrease in α-exon inclusion, establishing SRp55 as a major regulator of FGFR1 alternative splicing. UV cross-linking and immunoprecipitation; RNAi knockdown; RT-PCR quantification of α-exon inclusion; ESE deletion analysis Cancer research High 15604250
2005 SRp30c and SRp55/SRSF6 form a heterodimer that binds splicing silencers at the 5' end of tau exons 2 and 10, inhibiting both exons; in exon 2, hTra2β1 binds the inhibitory heterodimer through its RS1 domain; the SRp30c–SRp55 heterodimer may sterically block hTra2β1 binding to a purine-rich enhancer in exon 10. Deletion analysis of splicing silencers; protein–protein and protein–RNA binding assays; minigene splicing assays; co-immunoprecipitation of SRp30c–SRp55 complex The Journal of biological chemistry Medium 15695522
2006 In Drosophila, B52/SRSF6 acts upstream of the E2F repressor dE2F2 and is required for proper splicing of the de2f2 pre-mRNA; loss of B52 severely reduces dE2F2 protein levels and deregulates dE2F2-dependent gene expression, placing B52 as a specific regulator of the G1/S block. Genetic epistasis (de2f1 mutant rescue by B52 loss-of-function); mosaic clonal analysis (S-phase entry assay); intronless de2f2 rescue experiment; RT-PCR of de2f2 splicing in B52-deficient cells Molecular and cellular biology High 16611989
2007 B52/SRSF6 regulates alternative splicing of the Drosophila eye-specification gene eyeless, generating two isoforms differing by a 60-aa insert in the paired domain; the long isoform has impaired ability to trigger ectopic eye formation and to bind eyeless target DNA, while overproduction in the eye disc causes a small eye phenotype. In vivo splicing analysis; transgenic overexpression of individual isoforms in eye disc; ectopic eye assay; DNA-binding assay in vitro PloS one High 17327915
2007 B52/SRSF6 loss or gain of function in the Drosophila developing eye alters splicing profiles of many transcripts involved in brain organogenesis, and B52 (but not dASF/SF2) impairs normal photoreceptor axonal projections and neurogenesis in visual ganglia, demonstrating tissue-specific and target-specific roles. Microarray splicing analysis; loss- and gain-of-function in developing eye; phenotypic analysis of ommatidia structure and axonal projections Molecular and cellular biology Medium 17283056
2008 SRp55/SRSF6 regulates alternative splicing of KSR1, ZAK, and mda7/IL24, genes involved in apoptosis, as shown by splice-specific microarray analysis upon SRp55 siRNA knockdown; DNA damage in p53-deficient cells alters splicing of Fas toward the anti-apoptotic soluble isoform through changes in splicing activity. siRNA knockdown; splice-specific microarray; RT-PCR validation; Western blot for soluble Fas in media Gene Medium 18571879
2008 SR proteins ASF/SF2 and SRp55/SRSF6 physically associate with ESEs in tissue factor (TF) exon 5 (at bases 39 and 87–117); weakening either ESE causes severe skipping of TF exon 5 in a minigene reporter system in monocytic cells. In silico ESE identification; minigene reporter system; ESE mutagenesis; UV cross-linking/immunoprecipitation confirming physical association Journal of thrombosis and haemostasis : JTH Medium 18315555
2010 Drosophila Topoisomerase I (Topo I) associates with and phosphorylates the SR protein B52/SRSF6; expression of a high-affinity B52-binding site in transgenic flies restricts both B52 and Topo I to a single transcription site; B52 RNAi mislocalizes Topo I to the nucleolus; impaired Topo I delivery to a heat shock gene causes mRNA retention at the transcription site and delayed gene deactivation. Transgenic binding-site expression; B52 RNAi; co-immunoprecipitation of Topo I–B52; in vitro phosphorylation assay; mRNA FISH; heat shock gene deactivation kinetics PLoS genetics High 20862310
2010 SRp40 and SRp55/SRSF6 promote translation of unspliced HIV-1 Gag from intron-containing viral RNA; for SRp40, this activity depends on the second RRM and the RS domain; the effect requires specific nucleotide sequences in the gag-pol coding region (abolished by codon optimization), suggesting SR protein coupling of HIV-1 gRNA biogenesis to translational utilization. SR protein overexpression; Gag expression assay; domain deletion mutants; codon-optimized HIV-1 construct Journal of virology Medium 20427542
2010 SRp55/SRSF6 inhibits splicing from the 5' splice site of HIV-1 exon 3 by interacting with the GAR splicing enhancer, causing accumulation of partially spliced vpr mRNA; this inhibition requires both the RS domain and RNA-binding domains of SRp55. Splicing reporter assays; domain deletion mutants; RT-PCR quantification of HIV-1 mRNA species The Journal of biological chemistry Medium 20685659
2011 SRp55/SRSF6 also inhibits splicing from HIV-1 exon 5, generating partially spliced vpu/env mRNAs; inhibition of HIV-1 splicing by SRp55 promotes export of partially spliced mRNAs to the cytoplasm and can induce p24Gag production from a rev-defective provirus. Splicing reporter assays; RT-PCR; Western blot for p24Gag; subcellular fractionation Virus research Medium 21345357
2012 Dyrk1A interacts with SRp55/SRSF6 and phosphorylates its proline-rich domain; phosphorylation by Dyrk1A suppresses SRp55's ability to promote tau exon 10 inclusion; SRp55 promotes tau exon 10 inclusion through its RS domain (required for subnuclear speckle localization); knockdown of SRp55 promotes exon 10 exclusion. Co-immunoprecipitation; in vitro kinase assay; minigene splicing assays; siRNA knockdown; domain deletion (RS domain mutants); immunofluorescence for speckle localization The Journal of biological chemistry High 22767602
2013 SRSF6 is amplified and overexpressed in lung and colon cancers; SRSF6 overexpression in immortal lung epithelial cells enhances proliferation, protects from chemotherapy-induced cell death, and confers tumorigenic ability in mice; SRSF6 knockdown inhibits tumorigenicity; SRSF6 up/downregulation alters splicing of tumor suppressors and oncogenes to generate oncogenic isoforms. Gene copy number analysis; stable overexpression in lung epithelial cells; proliferation assays; xenograft tumorigenicity; shRNA knockdown; RT-PCR for splice isoforms The Journal of pathology High 23132731
2013 SRSF6 directly binds predicted binding sites in the intronic region adjacent to Bim exon 4 (as shown by UV cross-linking followed by Western blotting); mutations in these SRSF6-binding sites abolish BimS mRNA generation from a minigene; zinc-induced hyperphosphorylation of SRSF6 (via cdc2-like kinase) suppresses its binding to the Bim pre-mRNA, promoting exon 4 skipping and preferential BimS production. UV cross-linking and Western blot; Bim minigene mutagenesis; RT-PCR; CLK inhibitor (TG003); phosphorylation analysis The FEBS journal High 23648111
2014 SRSF6 is a proto-oncogene overexpressed in human skin cancer; transgenic overexpression in mice induces skin hyperplasia and promotes aberrant alternative splicing of 139 target genes including tenascin C; SRSF6 binds alternative exons in tenascin C pre-mRNA, promoting expression of invasive/metastatic cancer isoforms; SRSF6 overexpression depletes LGR6+ stem cells and causes excessive keratinocyte proliferation; effects on wound healing depend on tenascin-C isoforms. Transgenic mouse overexpression; RNA-seq for splicing targets; SRSF6 binding to tenascin C exons; skin histology; LGR6+ stem cell quantification; in vitro wound healing assay with isoform rescue Nature structural & molecular biology High 24440982
2015 In Drosophila, B52/SRSF6 overexpression increases cell growth (but not differentiation) in the mechanosensory bristle lineage, upregulates myc transcription, and causes loss of thoracic bristles; genetic suppressors identified include upregulation of brat (a post-transcriptional repressor of myc) and downregulation of lilliputian (a superelongation complex subunit). Tissue-specific overexpression in bristle lineage; genetic modifier screen; RT-PCR of myc levels; epistasis analysis with brat and lilli Genetics Medium 25680814
2016 SRSF6 promotes EMT and metastasis in colorectal cancer cells independently of lncRNA LINC01133; LINC01133 directly binds SRSF6 and inhibits EMT in a manner dependent on SRSF6 presence, acting as a decoy/target mimic. Co-IP to identify LINC01133–SRSF6 interaction; SRSF6 knockdown and overexpression; in vitro migration/invasion assays; in vivo metastasis model Cancer letters Medium 27443606
2016 RBM4a ablation in brown adipocytes enhances Nova1 exon-4-excluded isoform expression; Nova1 proteins reduce SRSF6 protein levels by promoting inclusion of intron 2 in SRSF6 transcripts (coupled NMD); SRSF6 positively regulates brown adipocyte development, placing it downstream of RBM4a–Nova1 in an AS cascade. RBM4a knockout; RNA-seq; RT-PCR of Nova1 and SRSF6 isoforms; Nova1 overexpression; SRSF6 overexpression in adipogenesis assay Biochimica et biophysica acta Medium 27535496
2017 SRSF6 regulates ZO-1 exon 23 alternative splicing by directly binding its RNA motif in exon 23, promoting ZO-1 aberrant splicing to drive CRC proliferation and metastasis; the SRSF6 RRM2 domain is key for regulating AS and biological function; indacaterol was identified as an SRSF6 inhibitor targeting RRM2 via virtual screening. RIP-seq (RNA immunoprecipitation sequencing); gel shift assay; minigene reporter assay; RRM2 domain deletion analysis; virtual screening; in vitro and in vivo tumor assays Gut High 29114070
2017 SRp55/SRSF6 regulates alternative splicing of genes controlling human pancreatic β-cell survival and function, including splicing changes in pro-apoptotic BIM, BAX, JNK signaling components, and ER stress genes; SRp55 depletion triggers β-cell apoptosis and inhibits mitochondrial function/insulin secretion; SRSF6 expression is regulated by the diabetes susceptibility transcription factor GLIS3. siRNA knockdown of SRp55 in human β-cells; RNA-seq; apoptosis assays; mitochondrial function assays; insulin secretion assay Diabetes High 29246973
2018 B52/SRSF6 increases the splicing efficiency of the temperature-sensitive period (dmpi8) intron in Drosophila; downregulation of B52 in clock neurons increases mid-day siesta and reduces dmpi8 splicing efficiency; natural SNPs in the per 3' UTR modulate B52 binding levels and correlate with sleep behavior variation. Cell culture splicing assay; in vivo B52 knockdown in clock neurons; behavioral sleep assay; allele-specific binding analysis Scientific reports Medium 29382842
2018 SRSF6 induces inclusion of MYH11 exon 5b in airway smooth muscle cells; siRNA inhibition of SRSF6 reduces SMB isoform expression, establishing SRSF6 as a regulator of smooth muscle myosin heavy chain splicing relevant to asthma. Bioinformatics ESE analysis; siRNA knockdown; RT-PCR quantification of SMB isoform Physiological reports Medium 30350466
2020 SRSF6 defines a purine-rich (GAA-triplet) consensus RNA-binding motif in human pancreatic β-cells; SRSF6 binds predominantly in coding sequences; binding site position determines splicing outcome; SRSF6 regulates splicing of multiple diabetes susceptibility genes. iCLIP (individual-nucleotide resolution UV cross-linking and immunoprecipitation); RNA-seq after SRSF6 knockdown; motif analysis; antisense oligonucleotide modulation of LMO7 splicing Life science alliance High 33376132
2020 SRSF6 overexpression in HeLa cells induces alternative splicing changes enriched in DNA damage response and DNA repair pathways; transcriptome analysis confirmed large-scale splicing changes upon SRSF6 overexpression. SRSF6 overexpression; RNA-seq; RT-PCR validation of specific AS events Oncology reports Medium 32901876
2020 Ablation of SRSF6 in mouse embryonic fibroblasts does not modulate incomplete splicing of HTT exon 1 to exon 2, demonstrating that SRSF6 is not required for this Huntington's disease-associated aberrant splicing event; Srsf6 nullizygosity is embryonic lethal in mice. Srsf6 knockout mice; MEF generation; siRNA ablation of SRSF6 in MEFs; RT-PCR for Httexon1 transcript Scientific reports High 32820193
2021 CRNDE lncRNA directly binds SRSF6 protein and reduces its protein stability; loss of CRNDE leads to increased SRSF6 activity, which regulates PICALM exon 14 skipping to produce the long PICALM isoform (PICALML), contributing to impaired autophagy flux and chemoresistance in gastric cancer. RNA pulldown; co-IP; SRSF6 protein stability assay; minigene splicing assay for PICALM exon 14; autophagy flux assays; PDX model Molecular cancer High 33397371
2021 DRAK2 directly binds SRSF6 (co-IP) and inhibits SRSF6 phosphorylation by SRPK1, thereby altering alternative splicing of mitochondrial function-related genes and promoting NASH progression; hepatic deletion of DRAK2 suppresses steatosis-to-NASH progression. Co-immunoprecipitation (DRAK2–SRSF6 interaction); phosphoproteome analysis; transcriptome analysis; hepatic DRAK2 conditional knockout; SRPK1 kinase assay in the context of DRAK2 Cell metabolism High 34614409
2022 SRSF6 regulates alternative splicing of BAX; loss of SRSF6 promotes accumulation of BAX-κ variant, sensitizing macrophages to cell death and triggering cGAS sensing of cytosolic mitochondrial DNA with upregulation of interferon-stimulated genes; macrophages regulate SRSF6 expression upon pathogen sensing to control mtDNA liberation and programmed cell death threshold. SRSF6 loss-of-function in macrophage cell lines; transcriptomic analysis; RT-PCR of BAX isoforms; cGAS sensing assay; apoptosis assays; mtDNA quantification in cytosol eLife High 36409059
2022 SRSF6 promotes inclusion of the Fas cassette exon; shRNA knockdown decreases Fas exon inclusion while overexpression increases it; a UGCCAA sequence in the Fas cassette exon is essential for SRSF6 function (identified by deletion and substitution mutagenesis of Fas minigene); SRSF6 interacts with this sequence (biotin-RNA pulldown); 5' splice site strength but not 3' splice site is required for SRSF6-regulated Fas splicing. shRNA knockdown; SRSF6 overexpression; Fas minigene deletion/substitution mutagenesis; biotin-labeled RNA pulldown and immunoblotting; splice-site strength mutagenesis Cancers High 35454897
2023 SRSF6 levels are strongly reduced under acute hypoxia through inclusion of a poison cassette exon (PCE) promoted by SRSF4; CRISPR/Cas9 removal of the PCE 3' splice site abolishes SRSF6 reduction in hypoxia; reduced SRSF6 drives exon skipping and dispersal of nuclear speckles; aberrantly high SRSF6 in hypoxia attenuates hypoxia-mediated AS, impairs nuclear speckle dispersal, increases proliferation and genomic instability, and suppresses the stress response. CRISPR/Cas9 deletion of PCE splice site; SRSF6 overexpression in hypoxia; nuclear speckle imaging; RNA-seq for AS events; proliferation assays; genomic instability assays Nucleic acids research High 36620874
2024 SRSF6 regulates the splicing pattern of the histone chaperone HIRA, affecting H3.3 activity; this disrupts AR and E2F oncogenic pathways in prostate cancer cells; SRSF6 modulation affects cell proliferation, migration, colony and tumorsphere formation in vitro and xenograft tumor growth in vivo. SRSF6 modulation (knockdown/overexpression); RT-PCR of HIRA isoforms; H3.3 activity assays; AR and E2F pathway readouts; xenograft tumor model Science advances Medium 39356765
2025 NSUN2 acts as an m5C 'writer' on SRSF6 mRNA (with ALYREF as 'reader'), stabilizing SRSF6 expression; SRSF6 in turn regulates alternative splicing of UAP1 (redirecting from AGX1 to AGX2 isoform), and AGX2 enhances N-linked glycosylation and stability of ABC transporters, driving multidrug resistance in anaplastic thyroid cancer. MeRIP-seq; NSUN2 knockout; transcriptomics; proteomics; nuclear-cytoplasmic fractionation; denaturing IP ubiquitination assay; glycoprotein staining; RT-PCR of UAP1 isoforms; spontaneous ATC mouse model Theranostics High 40083919
2025 AGGF1 promotes skipping of SRSF6 exon 3, producing a shorter SRSF6 isoform; full-length SRSF6 overexpression rescues reduced proliferation, migration, and capillary tube formation in AGGF1-silenced endothelial cells; srsf6 knockdown impairs intersomitic vessel development in zebrafish, while overexpression enhances vascular development and partially rescues aggf1 knockdown defects. Full-length transcriptome sequencing; AGGF1 siRNA knockdown; SRSF6 isoform overexpression; HPAEC functional assays (proliferation, migration, tube formation); zebrafish srsf6 knockdown and overexpression FASEB journal Medium 40035560
2025 SRSF6 and SRSF1 coordinately enhance inclusion of MUSK exon 10 through multiple ESE motifs; SRSF6 exerts a stronger effect than SRSF1 and can compensate for SRSF1 loss; specific functional ESE motifs were defined by mutagenesis; antisense oligonucleotides can switch MUSK isoform expression. ESE mutagenesis; SRSF6 and SRSF1 overexpression; SRSF6 knockdown; minigene splicing assay; antisense oligonucleotide experiments NAR molecular medicine Medium 40161265
2026 CircNSD2 acts as a scaffold enhancing the interaction between SRSF6 and the deubiquitinase USP10, preventing K48-linked polyubiquitination of SRSF6 at lysine 16 and inhibiting its proteasomal degradation; stabilized SRSF6 reprograms TPM1 alternative splicing to promote TNBC metastasis. RNA pulldown; proteomic analysis; RNA immunoprecipitation; co-IP of SRSF6–USP10; ubiquitination assay (denaturing IP); RT-PCR of TPM1 isoforms; in vitro and in vivo metastasis assays Molecular cancer Medium 41808072
2026 NMR backbone and sidechain assignments of SRSF6 RRM1 and backbone assignments of pseudo-RRM2 (ΨRRM2) were obtained; secondary structure analysis confirms canonical β1α1β2β3α2β4-fold for each RRM; the inter-domain linker is 37 residues; 15N-relaxation data show the two RRMs tumble as one entity with only transient interaction between them; AlphaFold3 models are largely supported but show subtle inconsistencies at the β4-strand. Solution NMR (1H, 13C, 15N backbone/sidechain assignments); 15N-relaxation analysis; secondary chemical shift analysis; comparison with AlphaFold3 models Journal of magnetic resonance (San Diego, Calif. : 1997) Medium 42102650

Source papers

Stage 0 corpus · 76 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2016 Long non-coding RNA LINC01133 inhibits epithelial-mesenchymal transition and metastasis in colorectal cancer by interacting with SRSF6. Cancer letters 166 27443606
2021 LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM. Molecular cancer 156 33397371
2017 SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut 142 29114070
2013 The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers. The Journal of pathology 129 23132731
1994 The SR protein B52/SRp55 is essential for Drosophila development. Molecular and cellular biology 104 7935465
2014 Splicing factor SRSF6 promotes hyperplasia of sensitized skin. Nature structural & molecular biology 103 24440982
1990 Premotor neurons B51 and B52 in the buccal ganglia of Aplysia californica: synaptic connections, effects on ongoing motor rhythms, and peptide modulation. Journal of neurophysiology 90 2329360
2012 Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusion. The Journal of biological chemistry 82 22767602
2021 DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. Cell metabolism 79 34614409
1997 A specific RNA hairpin loop structure binds the RNA recognition motifs of the Drosophila SR protein B52. Molecular and cellular biology 77 9111335
2005 Tau exons 2 and 10, which are misregulated in neurodegenerative diseases, are partly regulated by silencers which bind a SRp30c.SRp55 complex that either recruits or antagonizes htra2beta1. The Journal of biological chemistry 62 15695522
1999 SF2 and SRp55 regulation of CD45 exon 4 skipping during T cell activation. European journal of immunology 59 10092085
2010 SRp40 and SRp55 promote the translation of unspliced human immunodeficiency virus type 1 RNA. Journal of virology 56 20427542
2001 The aprX-lipA operon of Pseudomonas fluorescens B52: a molecular analysis of metalloprotease and lipase production. Microbiology (Reading, England) 55 11158351
1994 The concentration of B52, an essential splicing factor and regulator of splice site choice in vitro, is critical for Drosophila development. Molecular and cellular biology 55 8035814
1992 Cloning, expression, and nucleotide sequence of a lipase gene from Pseudomonas fluorescens B52. Applied and environmental microbiology 54 1599260
2020 miR-193a-5p promotes pancreatic cancer cell metastasis through SRSF6-mediated alternative splicing of OGDHL and ECM1. American journal of cancer research 53 32064152
2017 SRp55 Regulates a Splicing Network That Controls Human Pancreatic β-Cell Function and Survival. Diabetes 44 29246973
1995 Genetic enhancement of RNA-processing defects by a dominant mutation in B52, the Drosophila gene for an SR protein splicing factor. Molecular and cellular biology 41 7565780
2023 Poison cassette exon splicing of SRSF6 regulates nuclear speckle dispersal and the response to hypoxia. Nucleic acids research 39 36620874
2012 Shrimp Dscam and its cytoplasmic tail splicing activator serine/arginine (SR)-rich protein B52 were both induced after white spot syndrome virus challenge. Fish & shellfish immunology 39 23123640
2003 Human transformer 2beta and SRp55 interact with a calcitonin-specific splice enhancer. Biochimica et biophysica acta 34 12531473
2003 Differential effects of hyperphosphorylation on splicing factor SRp55. The Biochemical journal 34 12549978
1998 Specific binding of an exonic splicing enhancer by the pre-mRNA splicing factor SRp55. RNA (New York, N.Y.) 34 9436904
1995 CTLs from lymphoid organs recognize an optimal HLA-A2-restricted and HLA-B52-restricted nonapeptide and several epitopes in the C-terminal region of HIV-1 Nef. Journal of immunology (Baltimore, Md. : 1950) 34 7535824
2000 Pre-mRNA splicing by the essential Drosophila protein B52: tissue and target specificity. Molecular and cellular biology 30 10594020
2012 Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Melanoma research 29 22516966
2008 Splicing and splice factor SRp55 participate in the response to DNA damage by changing isoform ratios of target genes. Gene 29 18571879
2003 SRp55 is a regulator of calcitonin/CGRP alternative RNA splicing. Biochemistry 29 12549914
2025 NSUN2-mediated m5C modification drives alternative splicing reprogramming and promotes multidrug resistance in anaplastic thyroid cancer through the NSUN2/SRSF6/UAP1 signaling axis. Theranostics 28 40083919
2008 SR proteins ASF/SF2 and SRp55 participate in tissue factor biosynthesis in human monocytic cells. Journal of thrombosis and haemostasis : JTH 28 18315555
2016 RBM4-Nova1-SRSF6 splicing cascade modulates the development of brown adipocytes. Biochimica et biophysica acta 27 27535496
2021 Oncogenic lncRNA ZNF561-AS1 is essential for colorectal cancer proliferation and survival through regulation of miR-26a-3p/miR-128-5p-SRSF6 axis. Journal of experimental & clinical cancer research : CR 25 33622363
2021 Targeting Splicing Factor SRSF6 for Cancer Therapy. Frontiers in cell and developmental biology 24 34917618
2020 SRSF6 regulates alternative splicing of genes involved in DNA damage response and DNA repair in HeLa cells. Oncology reports 23 32901876
2010 Serine- and arginine-rich proteins 55 and 75 (SRp55 and SRp75) induce production of HIV-1 vpr mRNA by inhibiting the 5'-splice site of exon 3. The Journal of biological chemistry 22 20685659
2010 The SR protein B52/SRp55 is required for DNA topoisomerase I recruitment to chromatin, mRNA release and transcription shutdown. PLoS genetics 22 20862310
2007 The SR family proteins B52 and dASF/SF2 modulate development of the Drosophila visual system by regulating specific RNA targets. Molecular and cellular biology 21 17283056
2013 Zinc-induced modulation of SRSF6 activity alters Bim splicing to promote generation of the most potent apoptotic isoform BimS. The FEBS journal 20 23648111
2004 Enhancer-dependent splicing of FGFR1 alpha-exon is repressed by RNA interference-mediated down-regulation of SRp55. Cancer research 19 15604250
2021 Splicing factor SRSF6 mediates pleural fibrosis. JCI insight 18 33905374
2007 Eye development under the control of SRp55/B52-mediated alternative splicing of eyeless. PloS one 18 17327915
2006 Specific role of the SR protein splicing factor B52 in cell cycle control in Drosophila. Molecular and cellular biology 18 16611989
1994 Distribution of B52 within a chromosomal locus depends on the level of transcription. Molecular biology of the cell 18 8186467
2022 SRSF6 Regulates the Alternative Splicing of the Apoptotic Fas Gene by Targeting a Novel RNA Sequence. Cancers 16 35454897
2020 The RNA-binding profile of the splicing factor SRSF6 in immortalized human pancreatic β-cells. Life science alliance 16 33376132
2018 The SR protein B52/SRp55 regulates splicing of the period thermosensitive intron and mid-day siesta in Drosophila. Scientific reports 16 29382842
1987 Influence of iron(III) and pyoverdine on extracellular proteinase and lipase production by Pseudomonas fluorescens B52. Archives of microbiology 16 3109346
2016 The Severity of Takayasu Arteritis Is Associated with the HLA-B52 Allele in Japanese Patients. The Tohoku journal of experimental medicine 15 27193038
2020 Silencing Srsf6 does not modulate incomplete splicing of the huntingtin gene in Huntington's disease models. Scientific reports 14 32820193
1993 Apolipoprotein B-52 mutation associated with hypobetalipoproteinemia is compatible with a misaligned pairing deletion mechanism. Journal of lipid research 14 8354962
2022 SRSF6 balances mitochondrial-driven innate immune outcomes through alternative splicing of BAX. eLife 12 36409059
1997 Characterization of an HLA-B62 variant (B*1538) exhibiting an additional B52 serologic reactivity. Tissue antigens 12 9458123
2019 B52 promotes alternative splicing of Dscam in Chinese mitten crab, Eriocheir sinensis. Fish & shellfish immunology 11 30685464
2015 A role for the serine/arginine-rich (SR) protein B52/SRSF6 in cell growth and myc expression in Drosophila. Genetics 11 25680814
2011 Inhibition of splicing by serine-arginine rich protein 55 (SRp55) causes the appearance of partially spliced HIV-1 mRNAs in the cytoplasm. Virus research 11 21345357
2005 Cloning and expression of a novel lipase gene from Pseudomonas fluorescens B52. Molecular biotechnology 11 16170209
1983 Purification and characterization of NADP-dependent 7 beta-hydroxysteroid dehydrogenase from Peptostreptococcus productus strain b-52. Biochimica et biophysica acta 10 6572075
2018 SRSF6 is upregulated in asthmatic horses and involved in the MYH11 SMB expression. Physiological reports 9 30350466
1986 A rapid colorimetric assay for the extracellular lipase of Pseudomonas fluorescens B52 using beta-naphthyl caprylate. The Journal of dairy research 9 3082952
2003 Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: a peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients. European journal of immunology 8 14579264
1987 Effect of temperature shifts on extracellular proteinase-specific mRNA pools in Pseudomonas fluorescens B52. Applied and environmental microbiology 8 2444159
2019 Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome. Experimental and molecular pathology 7 31201803
2016 Single neuron transcriptomics identify SRSF/SR protein B52 as a regulator of axon growth and Choline acetyltransferase splicing. Scientific reports 7 27725692
2024 SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer. Science advances 6 39356765
2021 HLA-B52 allele in giant cell arteritis may indicate diffuse large-vessel vasculitis formation: a retrospective study. Arthritis research & therapy 5 34517892
2023 Genetic compensation response could exist in colorectal cancer: UPF3A upregulates the oncogenic homologue gene SRSF3 expression corresponding to SRSF6 to promote colorectal cancer metastasis. Journal of gastroenterology and hepatology 4 36807382
2021 A candidate gene study reveals association between a variant of the SRp55 splicing factor gene and systemic sclerosis. Clinical and experimental rheumatology 4 34665708
1988 Effect of carbon dioxide on growth and extracellular enzyme production by Pseudomonas fluorescens B52. International journal of food microbiology 4 3152795
2025 Angiogenic factor AGGF1 is a general splicing factor regulating angiogenesis and vascular development by alternative splicing of SRSF6. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 3 40035560
2024 Aortitis after switching short-acting granulocyte colony-stimulating factors in a lymphoma patient with HLA-B52. International journal of hematology 3 38521841
2025 SRSF6 and SRSF1 coordinately enhance the inclusion of human MUSK exon 10 to generate a Wnt-sensitive MuSK isoform. NAR molecular medicine 2 40161265
2026 CircNSD2 promotes metastasis and immune escape by increasing the USP10/SRSF6-mediated alternative splicing of TPM1 in TNBC. Molecular cancer 0 41808072
2026 1H, 13C, 15N backbone chemical shift assignments and relaxation analysis of the single and tandem RRMs of the human serine-arginine rich splicing factor 6 (SRSF6). Journal of magnetic resonance (San Diego, Calif. : 1997) 0 42102650
2025 The splicing factor SRSF6 mediates ferroptosis resistance in head and neck squamous cell carcinoma through induction of stearoyl-CoA desaturase. The Journal of biological chemistry 0 40712780
2001 A unique murine monoclonal antibody recognizing HLA-B53, B37, B51, B52, +/-B44. Human immunology 0 11423180

Missed literature

Know a paper Affinage missed for SRSF6? Flag it for the maintainers and the community.

No submissions yet.